Preclinical antitumor activity of S‐222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Issue 8 (August 2014)

• Record Type: Journal Article
• Authors: Tanaka, Hidekazu; Hirata, Michinari; Shinonome, Satomi; Wada, Toru; Iguchi, Motofumi; Dohi, Keiji; Inoue, Makiko; Ishioka, Yukichi; Hojo, Kanji; Yamada, Tomomi; Sugimoto, Tatsuya; Masuno, Koichi; Nezasa, Ken‐ichi; Sato, Norihito; Matsuo, Kenji; Yonezawa, Shuji; Frenkel, Eugene P.; Shichijo, Michitaka
• Is Part Of: Cancer science. Volume 105:Issue 8(2014:Aug.)
• Page Start: 1040
• Page End: 1048
• Publication Date: 2014-08
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.12449
• Languages: English
• ISSNs: 1347-9032

Abstract

<abstract abstract-type="main" id="cas12449-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR and HER2 inhibitor, S‐222611, that selectively inhibited both kinases with IC₅₀s below 10 nmol/L. S‐222611 also inhibited intracellular kinase activity and the growth of EGFR‐expressing and HER2‐expressing cancer cells. In addition, S‐222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. In evaluations with two patient‐oriented models, the intrafemoral implantation model and the intracranial implantation model, S‐222611 exhibited excellent activity and could be effective against bone and brain metastasis. Compared to neratinib and afatinib, irreversible EGFR/HER2 inhibitors, S‐222611 showed equivalent or slightly weaker antitumor activity but a safer profile. These results indicated that S‐222611 is a potent EGFR and HER2 inhibitor with substantially better antitumor activity than lapatinib at clinically relevant doses. Considering the safer profile than for irreversible inhibitors, S‐222611 could be an important option in future cancer therapy.</p> </abstract>